ClinicalTrials.gg
CompletedNCT05335096Updated Oct 27, 2026

An AI-based mHealth Intervention to Improve HIV Testing

An interventional study of An AI-chatbot-based mHealth intervention and An attention-chatbot-based mHealth intervention in HIV Infections, sponsored by Yale University. Completed at 1 site in Malaysia. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Yale University · Not applicable, Interventional, and Screening

How we know

Updated Oct 27, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in HIV Infections by Yale University — 2 open to participants now, 3 under way, none of them phase 3. HIV Infections · Yale University.

Enrollment
7th of 27
307 · median 60
Started
2025
the only one that year
No phase
15 of 30
1 open now
Registered
27th of 30
by date

Among the 30 studies in HIV Infections by Yale University, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2025, is one of 15 with no phase, and was the 27th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

2 of the 30 studies in HIV Infections by Yale University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in HIV Infections by Yale University, or all of them as a file.
02

Study summary

The purpose of this study is to develop an artificial intelligence (AI)-chatbot-based mobile health (mHealth) intervention to promote HIV testing in Malaysia.

Read the detailed description

A randomized controlled trial (RCT) will be conducted in Malaysia to assess the efficacy of an AI-chatbot-based mHealth intervention versus treatment as usual (TAU) with HIV testing as the primary outcome. The primary outcome will be the proportion of participants who get tested within 180 days.

Participants will be randomized to the chatbot group and TAU group. Participants in the intervention group will get access to an AI-chatbot and can interact with the AI-chatbot at any time. In each round of the interactive communication, the chatbot will provide automated personalized messages containing pre-exposure prophylaxis (PrEP), mental health, or HIV testing-related information, motivation and skills based on the participants' answers and will continuously update over time. The participants assigned to the TAU group will get access to an attention-chatbot and can interact with the attention-chatbot at any time. In each round of the interaction, the chatbot will provide pre-scripted time-attention health education messages to the participants.

In addition to the above interventions, the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180). The primary outcome of HIV testing will be collected through the survey.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cis-gender male
  • condomless sex with men in the past 6 months
  • status unknown or previously tested negative
  • speaks Bahasa Malaysia or English.

Exclusion criteria

Exclusion Criteria:

  • Does not have a smartphone
  • status previously tested positive
  • cannot speak Bahasa Malaysia or English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    Intervention group

    Behavioral: An AI-chatbot-based mHealth intervention · Behavioral: Educational materials

  • Active comparator
    TAU group

    Behavioral: An attention-chatbot-based mHealth intervention · Behavioral: Educational materials

Interventions

  • BehavioralAn AI-chatbot-based mHealth intervention

    The participants assigned to the intervention group will get access to an AI-chatbot and can interact with the AI-chatbot at any time. In each round of the interactive communication, the chatbot will provide automated personalized messages containing PrEP, mental health, or HIV testing-related information, motivation and skills based on the participants' answers and will continuously update over time.

  • BehavioralAn attention-chatbot-based mHealth intervention

    The participants assigned to the control group will get access to an attention-chatbot and can interact with the attention-chatbot at any time. In each round of the interaction, the chatbot will provide pre-scripted time-attention health education messages to the participants.

  • BehavioralEducational materials

    the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).

06

What researchers measure

Primary outcomes

  1. Number of participants that get tested for HIV within 180 days

    The number of participants who get tested for HIV within 180 days assessed by an online survey link that will be manually sent by the research assistant to the participant's phone every 30 days, up to 180 days. The survey consists of a question asking if the participant has been tested for HIV in the last 30 days with an answer of yes or no.

    Time frame: up to 180 days

07

Study locations

1 site
  • University of Malaysia
    Kuala Lumpur, 50603, Malaysia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Feb 2026, 13 months.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 13 months is below that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Nov 2024 → Jan 2025 and primary completion May 2026 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 19, 2022
StartActual
Jan 2, 2025was Nov 2024
Primary completionActual
Feb 23, 2026was May 2026
CompletionActual
Jun 5, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 26, 2024→Jan 2, 2025
Oct 27, 2026
Primary completion
May 29, 2026→Feb 23, 2026
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Nov 26, 2024→Jan 2, 2025
    Primary completion May 29, 2026→Feb 23, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05335096
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Apr 19, 2022
Start date
Jan 2, 2025
Primary completion
Feb 23, 2026
Completion
Jun 5, 2026
Last update
Oct 27, 2026

Study contacts

Zhao Ni, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion